Drug intelligence / Profile preview

Hyemingo

Development stage: Unknown
Lead developer: Daehwa Pharmaceutical
Modality: Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical

Overview

**Hyemingo** is a Dae Hwa topical cataplasma for musculoskeletal pain and inflammation. It is a fixed-dose, multi-ingredient medicinal gel patch containing botanical extracts of Phellodendron bark, Gardenia fruit, and Zanthoxylum fruit together with glycol salicylate, L-menthol, D-camphor, tocopherol, and glycyrrhetic acid. Dae Hwa classifies it within its transdermal drug-delivery product portfolio; the product is intended for local relief of aching, inflamed, or painful musculoskeletal areas. ([dhpharm.co.kr](https://www.dhpharm.co.kr/_en/html/dh/DH_product_detail?idx=250))

Brand names: Hyemingo
Other names: Hyemingo Cataplasma惠民膏

Beyond the preview

Go deeper on Hyemingo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyemingo.

Explore the full profile